Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medtronic PLC (MDT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Medtronic PLCTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Medtronic PLC vs Zimmer Biomet Holdings Inc — how do they compare? Medtronic PLC trades at $88.48 (market cap $112.24B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Medtronic PLC is far larger — about 6.6× Zimmer Biomet Holdings Inc's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

MDTZBH
Market Cap
$112.24B$16.95B
Volume
105,663,2362,505,240
Sector
HealthHealth
52-Week High
$105.35$103.98
52-Week Low
$73.75$79.58
Typical Hold Time
63 Days89 Days
Enterprise Value
$131.58B$24.02B
Dividend Yield
3.28%1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medtronic PLC

Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.

MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.

The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MDT
6% Buy94% Sell
Avg holding period · 63 Days
ZBH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →